REPLY TO THORNELOE ET AL

Affiliations

¹ Department of Surgery and Cancer, Anaesthetics, Pain Medicine and Intensive Care Section, Faculty of Medicine, Imperial College London, Chelsea and Westminster Hospital, London, United Kingdom; Department of Anaesthetics, The Queen Elizabeth Hospital, Birmingham, United Kingdom; Preclinical Compound Profiling, Secondary Pharmacology, Preclinical Safety, NIBR, Cambridge, Massachusetts; Department of Molecular Cell Biology, Campus Gasthuisberg, Leuven, Belgium; School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom.

Free article

Comment

John P M White et al. Physiol Rev. 2017.

Free article

. 2017 Oct 1;97(4):1233-1234.

doi: 10.1152/physrev.00020.2017.

¹ Department of Surgery and Cancer, Anaesthetics, Pain Medicine and Intensive Care Section, Faculty of Medicine, Imperial College London, Chelsea and Westminster Hospital, London, United Kingdom; Department of Anaesthetics, The Queen Elizabeth Hospital, Birmingham, United Kingdom; Preclinical Compound Profiling, Secondary Pharmacology, Preclinical Safety, NIBR, Cambridge, Massachusetts; Department of Molecular Cell Biology, Campus Gasthuisberg, Leuven, Belgium; School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom.

No abstract available

Comment on

PROPERTIES OF THE TRPV4 AGONIST GSK1016790A AND the TRPV4 ANTAGONIST GSK2193874.
Thorneloe KS, Cheung M, Holt DA, Willette RN. Thorneloe KS, et al. Physiol Rev. 2017 Oct 1;97(4):1231-1232. doi: 10.1152/physrev.00019.2017. Physiol Rev. 2017. PMID: 28794166 No abstract available.